Department of Cardiology, Internet Medicine, The Second Xiangya Hospital, Central South University, Changsha 410011, Hunan, China.
Lipids Health Dis. 2013 Oct 23;12:151. doi: 10.1186/1476-511X-12-151.
14,15-Epoxyeicosatrienoic acids (14,15-EETs) generated from arachidonic acid by cytochrome P450 epoxygenases have beneficial effects in certain cardiovascular diseases, and increased 14,15-EET levels protect the cardiovascular system. 14,15-EETs are rapidly hydrolyzed by soluble epoxide hydrolase (sEH) to the corresponding 14,15-dihydroxyeicosatrienoic acids (14,15-DHETs), which are generally less biologically active but more stable metabolite. A functionally relevant polymorphism of the CYP2J2 gene is independently associated with an increased risk of coronary heart disease (CHD), and the major CYP2J2 product is 14,15-EETs. 14,15-DHETs can be considered a relevant marker of CYP2J2 activity. Therefore, the aim of the present study was to evaluate the plasma 14,15-DHET levels to reflect the 14,15-EET levels in an indirectly way in patients with CHD, and to highlight the growing body of evidence that 14,15-EETs also play a role in anti-inflammatory and lipid-regulating effects in patients with CHD. This was achieved by investigating the relationship between 14,15-DHETs and high-sensitivity C-reactive protein (hs-CRP) and blood lipoproteins.
Samples of peripheral venous blood were drawn from 60 patients with CHD and 60 healthy controls. A 14,15-DHET enzyme-linked immunosorbent assay kit (14,15-DHET ELISA kit) was used to measure the plasma 14,15-DHET levels. Hs-CRP, total cholesterol, triglyceride, high-density lipoprotein cholesterol, and low-density lipoprotein-cholesterol levels were measured.
14,15-DHET levels (2.53 ± 1.60 ng/mL) were significantly higher in patients with CHD as compared with those of the healthy controls (1.65 ± 1.54 ng/mL, P < 0.05). There was a significant positive correlation between 14,15-DHETs and hs-CRP levels (R = 0.286, P = 0.027). However, there was no significant correlation between 14,15-DHETs and blood lipoproteins (all, P > 0.05).
Increased plasma 14,15-DHET levels reflect the decreased of 14,15-EET levels in an indirectly way. Indicated that decreased plasma 14,15-EET levels might be involved in the inflammatory reaction process in atherosclerosis.
细胞色素 P450 环氧化酶从花生四烯酸生成的 14,15-环氧二十碳三烯酸 (14,15-EETs) 在某些心血管疾病中具有有益作用,并且增加 14,15-EET 水平可保护心血管系统。14,15-EETs 可被可溶性环氧化物水解酶 (sEH) 迅速水解为相应的 14,15-二羟基二十碳三烯酸 (14,15-DHETs),其一般具有较低的生物活性但更稳定的代谢物。CYP2J2 基因的一种功能相关的多态性与冠心病 (CHD) 的风险增加独立相关,并且 CYP2J2 的主要产物是 14,15-EETs。14,15-DHETs 可被视为 CYP2J2 活性的相关标志物。因此,本研究的目的是评估冠心病患者的血浆 14,15-DHET 水平,以间接反映 14,15-EET 水平,并强调越来越多的证据表明 14,15-EETs 在冠心病患者的抗炎和调节脂质作用中也发挥作用。这是通过研究 14,15-DHETs 与高敏 C 反应蛋白 (hs-CRP) 和血脂蛋白之间的关系来实现的。
从 60 例 CHD 患者和 60 例健康对照者中抽取外周静脉血样本。使用 14,15-DHET 酶联免疫吸附测定试剂盒 (14,15-DHET ELISA 试剂盒) 测量血浆 14,15-DHET 水平。测量 hs-CRP、总胆固醇、甘油三酯、高密度脂蛋白胆固醇和低密度脂蛋白胆固醇水平。
与健康对照组相比,CHD 患者的 14,15-DHET 水平 (2.53±1.60ng/mL) 显著升高 (1.65±1.54ng/mL,P<0.05)。14,15-DHETs 与 hs-CRP 水平呈显著正相关 (R=0.286,P=0.027)。然而,14,15-DHETs 与血脂蛋白之间无显著相关性 (均 P>0.05)。
血浆 14,15-DHET 水平的升高间接反映了 14,15-EET 水平的降低。表明血浆 14,15-EET 水平降低可能参与动脉粥样硬化中的炎症反应过程。